EGFR and non-small cell lung carcinoma: Gefitinib, belonging to the EGFR-TKIs, is specific for the advanced NSCLC patients with EGFR-sensitive mutations (Gonzalez-Larriba et al., 2017; Mistry and Patil, 2017; Su et al., 2017).